K. Joshi

发表

Effect of improvement in left ventricular ejection fraction on long-term survival in revascularized patients with ischaemic left ventricular systolic dysfunction.

I. Gradus-Pizlo, S. Sawada, H. Feigenbaum, 2011, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries

P. Lefebvre, D. Lin, K. Joshi, 2021, Current medical research and opinion.

Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries with Prior Schizophrenia Relapse.

P. Lefebvre, D. Lin, K. Joshi, 2021, Clinical therapeutics.

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis

M. Mathews, S. Gopal, I. Nuamah, 2021, Patient preference and adherence.

Characteristics and current standard of care among veterans with major depressive disorder in the United States: A real-world data analysis.

J. Sheehan, K. Joshi, A. Near, 2022, Journal of affective disorders.

Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate

Xiaoyun Pan, C. Benson, K. Joshi, 2016, Current medical research and opinion.

Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia

David M. Smith, Xue Song, K. Joshi, 2019, Journal of medical economics.

Clinical and economic burden of major depressive disorder with acute suicidal ideation or behavior in a US Veterans Health Affairs database

C. Neslusan, I. Chopra, K. Joshi, 2022, Current medical research and opinion.

Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans

P. Lefebvre, N. Tandon, K. Joshi, 2019, Current medical research and opinion.

Burden of Schizophrenia or Psychosis-Related Symptoms in Adults Undergoing Substance Abuse Evaluation

S. Butler, K. Trudeau, K. Joshi, 2018, The Journal of nervous and mental disease.

Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder

K. Joshi, D. Fu, M. Lingohr-Smith, 2015, Journal of medical economics.

Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate

P. Lefebvre, D. Lin, K. Joshi, 2021, Current medical research and opinion.

PPA_A_322880 2239..2248

M. Mathews, S. Gopal, I. Nuamah, 2021 .

Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.

P. Lefebvre, N. Tandon, K. Joshi, 2017, Clinical therapeutics.

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic

P. Lefebvre, N. Tandon, K. Joshi, 2017, Patient preference and adherence.

Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States.

L. Citrome, J. Sheehan, P. Lefebvre, 2022, Journal of affective disorders.

Economic Burden of Commercially Insured Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States.

P. Greenberg, J. Sheehan, C. Neslusan, 2022, The Journal of clinical psychiatry.

The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study

O. Tcheremissine, C. Benson, D. Lin, 2021, Advances in Therapy.

Understanding healthcare burden and treatment patterns among young adults with schizophrenia

Li Wang, K. Joshi, T. Amos, 2018, Journal of medical economics.

Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study

Edward Kim, P. Lefebvre, D. Lin, 2021, Current medical research and opinion.

Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations

C. Benson, K. Joshi, Jeffrey P. Anderson, 2017, BMC Psychiatry.

Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA

C. Neslusan, P. Lefebvre, K. Joshi, 2021, PharmacoEconomics.

Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United States

S. Meakin, C. Benson, D. Lin, 2021, Frontiers in Psychiatry.

Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics

C. Correll, Edward Kim, C. Benson, 2022, Schizophrenia.

The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States.

J. Sheehan, P. Lefebvre, K. Joshi, 2021, The Journal of clinical psychiatry.

Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics

K. Lapane, J. Fastenau, C. Benson, 2015, Current medical research and opinion.

Original article Evaluation of a comprehensive information and assistance program for patients with schizophreniatreatedwithlong-actinginjectable antipsychotics

K. Lapane, J. Fastenau, C. Benson, 2015 .

The real-world burden of adults with major depressive disorder with moderate or severe insomnia symptoms in the United States.

H. Costantino, M. Jha, M. Cambron-Mellott, 2022, Journal of affective disorders.

Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy

L. Citrome, J. Sheehan, P. Lefebvre, 2021, Journal of medical economics.

A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States

Stephen W. Gutkin, K. Joshi, S. Gutkin, 2018, ClinicoEconomics and outcomes research : CEOR.

Patient Journey of Veterans with Schizophrenia: An Analysis of Treatment Patterns, Healthcare Resource Utilization and Costs

Li Wang, K. Joshi, A. Huang, 2022, Advances in Therapy.

Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States

E. Muser, Jay Lin, K. Joshi, 2016, Journal of clinical psychopharmacology.

Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy.

K. Tunceli, K. Iglay, Shengsheng Yu, 2015, Clinical therapeutics.

Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder

P. Lefebvre, K. Joshi, D. Pilon, 2020, Current medical research and opinion.

Economic burden of treatment-resistant depression among veterans in the United States

Li Wang, C. Benson, K. Joshi, 2021, Current medical research and opinion.

US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior.

J. Sheehan, H. Toro-Díaz, K. Joshi, 2022, Journal of comparative effectiveness research.

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics

Edward Kim, P. Lefebvre, N. Tandon, 2018, Drugs - Real World Outcomes.

Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia

E. Muser, P. Lefebvre, K. Joshi, 2017, BMC Psychiatry.

Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population.

E. Muser, B. Suehs, Yihua Xu, 2018, Journal of comparative effectiveness research.

A comparison of the use of traditional hand injection versus automated contrast injectors during cardiac catheterization.

R. Godley, K. Joshi, J. Breall, 2012, The Journal of invasive cardiology.

Contribution A Comparison of the Use of Traditional Hand Injection Versus Automated Contrast Injectors During Cardiac Catheterization

R. Godley, K. Joshi, J. Breall, 2012 .

Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis

P. Greenberg, J. Sheehan, P. Lefebvre, 2019, PloS one.

US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study

P. Greenberg, J. Sheehan, P. Lefebvre, 2019, PharmacoEconomics - Open.

Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.

B. Shiner, Y. Young-Xu, P. Lefebvre, 2018, Clinical therapeutics.

Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting

P. Lefebvre, N. Tandon, K. Joshi, 2017, Current medical research and opinion.

Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.

B. Shiner, Y. Young-Xu, E. Muser, 2017, Clinical therapeutics.

Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression

L. Citrome, J. Sheehan, P. Lefebvre, 2021, Advances in Therapy.

Social determinants and distance from certified treatment centers are associated with initiation of esketamine nasal spray among patients with challenging-to-treat major depressive disorder

L. Harding, J. Pesa, Pinyao Rui, 2023, Medicine.

Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate

A. Khoury, P. Lefebvre, N. Tandon, 2018, PharmacoEconomics - Open.

Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis

O. Baser, Li Wang, K. Joshi, 2019, Advances in Therapy.

Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics

P. Lefebvre, K. Joshi, D. Pilon, 2018, Current medical research and opinion.

The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia

D. Biondi, K. Joshi, L. Mao, 2018, BMC Psychiatry.

How well do clinical and demographic characteristics predict Patient Health Questionnaire‐9 scores among patients with treatment‐resistant major depressive disorder in a real‐world setting?

J. Sheehan, R. Potluri, A. Dasgupta, 2021, Brain and behavior.

The clinical, economic, and patient‐centric burden of insomnia symptom severity in adults with major depressive disorder in the United States

H. Costantino, M. Jha, M. Cambron-Mellott, 2023, Brain and behavior.

Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.

Edward Kim, P. Lefebvre, N. Tandon, 2018, Journal of comparative effectiveness research.

Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?

J. Sheehan, P. Lefebvre, K. Joshi, 2019, Journal of affective disorders.

Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions

Craig E. Nelson, P. Lefebvre, K. Joshi, 2020, Journal of Managed Care & Specialty Pharmacy.

Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on Esketamine intranasal spray and covered by US commercial health plans.

K. Joshi, D. Pilon, M. Zhdanava, 2023, Journal of medical economics.

Patient profiles, initial hospital encounter characteristics, and hospital re-encounters of patients with a hospital emergency department visit or inpatient admission for major depressive disorder

M. Mathews, Jay Lin, Qiaoyi Zhang, 2022, Journal of medical economics.

Treatment Patterns and Medicaid Spending in Comorbid Schizophrenia Populations: Once-Monthly Paliperidone Palmitate Vs Oral Atypical Antipsychotics

P. Lefebvre, K. Joshi, D. Pilon, 2018 .

Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.

P. Lefebvre, K. Joshi, D. Pilon, 2022, Clinical therapeutics.

Systematic Literature Review and Meta-Analysis of Medication Adherence with Once Weekly Versus Once Daily Therapy in Patients with Osteoporosis

K. Tunceli, K. Iglay, P. Mavros, 2014 .

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States

K. Joshi, D. Pilon, M. Zhdanava, 2023, Journal of medical economics.

Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States

K. Joshi, D. Pilon, M. Zhdanava, 2024, Drugs - real world outcomes.

Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance

P. Lefebvre, K. Joshi, D. Pilon, 2023, Current medical research and opinion.